Jeremy Talley
Family Medicine · Hermann, MONPI 1184847659
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,470 and has fallen 77.9% since, to $325 in 2025. Among family medicine clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$830
- Supernus Pharmaceuticals, Inc.$822
- Lilly USA, LLC$672
- Boehringer Ingelheim$580
- AstraZeneca$368
- AbbVie$320
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,233100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $830 |
| Supernus Pharmaceuticals, Inc. | 51 | $822 |
| Lilly USA, LLC | 39 | $672 |
| Boehringer Ingelheim | 35 | $580 |
| AstraZeneca | 24 | $368 |
| AbbVie(2 entities) | 16 | $320 |
| Amgen | 15 | $251 |
| Otsuka America Pharmaceutical, Inc. | 11 | $181 |
| Pfizer | 8 | $125 |
| Lundbeck LLC | 6 | $118 |
| GSK | 8 | $108 |
| Neurocrine Biosciences, Inc. | 6 | $95 |
| Vanda Pharmaceuticals Inc. | 4 | $78 |
| Neos Therapeutics, LP | 6 | $76 |
| Merck | 5 | $70 |
| Abbott | 4 | $60 |
| Johnson & Johnson | 4 | $55 |
| Sumitomo Pharma America, Inc. | 3 | $49 |
| Dexcom, Inc. | 2 | $42 |
| Mylan Specialty L.p. | 3 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Ironshore Pharmaceuticals Inc. | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Exact Sciences | 1 | $20 |
| Cranial Technologies, Inc | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Globus Medical | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Electromed, Inc. | 1 | $12 |
How this compares
$5,253 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 133 | $160,657 |
| EliquisApixaban | 180 | $147,738 |
| JardianceEmpagliflozin | 114 | $116,857 |
| TrulicityDulaglutide | 100 | $115,954 |
| AtivanLorazepam | 12 | $80,097 |
| MounjaroTirzepatide | 53 | $64,318 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $63,445 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $54,209 |
| FarxigaDapagliflozin Propanediol | 48 | $46,887 |
| JanuviaSitagliptin Phosphate | 30 | $41,704 |
| XareltoRivaroxaban | 52 | $33,635 |
| LinzessLinaclotide | 36 | $27,123 |
| Incruse ElliptaUmeclidinium Bromide | 38 | $20,922 |
| TradjentaLinagliptin | 18 | $20,514 |
| Spiriva RespimatTiotropium Bromide | 26 | $19,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $672 | $180,272153 claims |
| Novo NordiskOzempic | $830 | $160,657133 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $580 | $157,038158 claims |
| PfizerEliquis | $125 | $147,738180 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy | $108 | $119,731163 claims |
| AstraZenecaFarxiga, Symbicort | $368 | $63,667103 claims |
| MerckJanuvia | $70 | $41,70430 claims |
| AbbVieLinzess, Savella | $320 | $40,16863 claims |
| Johnson & JohnsonXarelto | $55 | $33,63552 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $10,58016 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $24 | $7,38713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Hermann
- Stephen AdamsSpringfield$636K
- Justin PuckettKirksville$568K
- Matthew BeckerditeOfallon$225K
- Roger CadySpringfield$175K
- James LasalleExcelsior Springs$130K
- Matthew TiefenbrunnSullivan$105K
- Ayobami OduwoleGrandview$92K
- Michael DonovanSaint Louis$78K
- Blair ThedingerKansas City$71K
- Christine MooreRaymore$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.